Asset Details
Do you wish to reserve the book?
Group B Streptococcus: global incidence and vaccine development
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Group B Streptococcus: global incidence and vaccine development
Do you wish to request the book?
Group B Streptococcus: global incidence and vaccine development
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Group B Streptococcus: global incidence and vaccine development
2006
Overview
Key Points
Streptococcus agalactiae
or Group B
Streptococcus
(GBS) is an important pathogen that affects neonates, peripartum women and the elderly worldwide. Prenatal maternal screening for GBS and antibiotic treatment has reduced the rate of neonatal GBS disease but the best long-term solution for control of the disease is vaccination.
Several GBS vaccine candidates have been developed, including conjugate vaccines prepared by linking purified capsular polysaccharide to proteins. Conjugate vaccines have been prepared against all nine currently identified GBS serotypes.
Human clinical trials with several conjugate vaccines have successfully completed phase I and II testing with promising results. In addition, a type III conjugate vaccine has been found to be safe and immunogenic in pregnant women.
Reverse vaccinology has revealed new GBS protein antigens that are immunogenic and efficacious in preclinical studies involving mice. Further advances in GBS vaccine development are likely through combining genomics with newer proteomic technologies.
Group B
Streptococcus
(GBS) is a pathogen of worldwide significance, and although prophylactic measures have reduced the number of infections, development of a vaccine remains an important goal. Here, the authors review the incidence of GBS and how new technologies are being applied in the search for a globally effective vaccine.
An ongoing public health challenge is to develop vaccines that are effective against infectious diseases that have global relevance. Vaccines against serotypes of group B
Streptococcus
(GBS) that are prevalent in the United States and Europe are not optimally efficacious against serotypes common to other parts of the world. New technologies and innovative approaches are being used to identify GBS antigens that overcome serotype-specificity and that could form the basis of a globally effective vaccine against this opportunistic pathogen. This Review highlights efforts towards this goal and describes a template that can be followed to develop vaccines against other bacterial pathogens.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Bacteria
/ Bacterial Capsules - immunology
/ Bacterial Proteins - immunology
/ Bacterial Vaccines - immunology
/ Biomedical and Life Sciences
/ Births
/ Female
/ Gene Expression Regulation, Bacterial - immunology
/ Genome, Bacterial - immunology
/ Genomes
/ Humans
/ Neonates
/ Polysaccharides, Bacterial - immunology
/ Pregnancy Complications, Infectious - epidemiology
/ Pregnancy Complications, Infectious - prevention & control
/ Proteins
/ Streptococcal Infections - epidemiology
/ Streptococcal Infections - prevention & control
/ Streptococcus agalactiae - genetics
/ Streptococcus agalactiae - immunology
/ Streptococcus agalactiae - pathogenicity
/ Vaccines
/ Vagina
/ Virology
